Among the problems faced by people with Huntington’s disease (HD), a common one is weight loss. Many individuals with the disease lose weight over time, even when they are trying to eat enough. This ...

Today, Roche announced in a community letter difficult news for the Huntington’s disease (HD) community, discontinuing two separate clinical programmes after new data emerged from ongoing studies. The ...

No, not a puppy or a kitten or even a pet turtle, but a PET tracer to visualize huntingtin (HTT) protein in living subjects. PET stands for Positron Emission Tomography, an imaging technique that can ...

In plain language. Written by scientists. Catch up on all the latest Huntington's disease clinical trial news in this one stop shop article covering all of the recent developments in making medicines ...

A paper recently published in Nature Medicine caught our attention. In it, researchers celebrated Australia’s new federal law banning life insurance companies from using genetic test results when ...

In nature, dominant organisms are known for taking over the natural resources in an area. For example, a tree that grows tall over time is exposed to large amounts of sunlight. However, if a seedling ...

After a tumultuous stretch, June brought welcome news on the regulatory front. The FDA has agreed that uniQure’s existing three-year data can serve as the basis for a Biologics License Application.

uniQure shared in a press release on June 17, 2026 that the Food and Drug Administration (FDA) has agreed the 3-year data from their Phase I/II study can serve as the basis for a Biologics License ...

On June 30th, Skyhawk Therapeutics shared a press release with new twelve-month data from the ongoing Phase 1/2 trial of SKY-0515, their HTT-lowering pill designed to treat Huntington’s disease (HD).

In plain language. Written by scientists. ⏱️ 6 min read | New 12-month data from Skyhawk’s SKY-0515 is in and all four measures that make up the cUHDRS are at or above baseline, beating expected ...